Last reviewed · How we verify
Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder
Post-traumatic stress disorder (PTSD) is a complex disorder expressed as a variety of neurobiological symptoms, including anxiety, re-experiencing, hyperarousal, and avoidance symptoms, along with comorbidities such as anxiety, depression, and increased risk for self-medicating substance abuse. Currently, there are only two approved medications in the United States (US) for PTSD, paroxetine and sertraline. Psychedelic medications, including psilocybin, have recently received breakthrough designation by the US Food and Drug Administration (FDA) for other psychiatric indications. Although no formal clinical trials have yet investigated psychedelic substances for the treatment of PTSD, the available evidence warrants such an investigation. The present study aims to investigate the effect of psilocybin on treatment-resistant PTSD.
Details
| Lead sponsor | Halucenex Life Sciences Inc. |
|---|---|
| Phase | PHASE2 |
| Status | UNKNOWN |
| Enrolment | 20 |
| Start date | Mon Oct 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sat Dec 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Treatment Resistant Disorders
- Post Traumatic Stress Disorder
Interventions
- Psilocybin
Countries
Canada